Sunday, November 14, 2010

AMEDEO HIV Infection: Your November Journal Article Summary

AMEDEO HIV Infection

2010-11-15
  
________________ ** New articles **  _________________


1. JOHNSTON KM, Levy AR, Lima VD, Hogg RS, et al.
Reply to 'Evidence is still required for treatment as prevention for riskier routes of HIV transmission'.
AIDS. 2010;24:2892-3.



2. WILSON DP.
Evidence is still required for treatment as prevention for riskier routes of HIV
transmission.
AIDS. 2010;24:2891-2.



3. COHEN GB.
HIV vaccines: sin boldly!
AIDS. 2010;24:2877-9.



4. DE SAINT-MARTIN L, Bressollette L, Perfezou P, Bellein V, et al.
Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of
HIV-infected persons: a comparative prospective cohort.
AIDS. 2010;24:2797-801.
ABSTRACT available


5. HAYES R, Watson-Jones D, Celum C, van de Wijgert J, et al.
Treatment of sexually transmitted infections for HIV prevention: end of the road
or new beginning?
AIDS. 2010;24 Suppl 4:S15-26.
ABSTRACT available


6. HAYES R, Kapiga S, Padian N, McCormack S, et al.
HIV prevention research: taking stock and the way forward.
AIDS. 2010;24 Suppl 4:S81-92.
ABSTRACT available


7. HANKINS CA, de Zalduondo BO.
Combination prevention: a deeper understanding of effective HIV prevention.
AIDS. 2010;24 Suppl 4:S70-80.
ABSTRACT available


8. WEISS HA, Dickson KE, Agot K, Hankins CA, et al.
Male circumcision for HIV prevention: current research and programmatic issues.
AIDS. 2010;24 Suppl 4:S61-9.
ABSTRACT available


9. FAST PE, Kaleebu P.
HIV vaccines: current status worldwide and in Africa.
AIDS. 2010;24 Suppl 4:S50-60.
ABSTRACT available


10. RAMJEE G, Kamali A, McCormack S.
The last decade of microbicide clinical trials in Africa: from hypothesis to
facts.
AIDS. 2010;24 Suppl 4:S40-9.
ABSTRACT available


11. ROSS DA.
Behavioural interventions to reduce HIV risk: what works?
AIDS. 2010;24 Suppl 4:S4-14.
ABSTRACT available


12. WEBER J, Tatoud R, Fidler S.
Postexposure prophylaxis, preexposure prophylaxis or universal test and treat:
the strategic use of antiretroviral drugs to prevent HIV acquisition and
transmission.
AIDS. 2010;24 Suppl 4:S27-39.
ABSTRACT available


13. KAPIGA S, Hayes R, Buve A.
HIV prevention--where now? Background and introduction.
AIDS. 2010;24 Suppl 4:S1-3.



14. CHO YK, Foley BT, Jung Y.
Phylogenetic analysis of full-length pol gene from Korean hemophiliacs and plasma
donors infected with Korean subclade B of HIV-1.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available


15. PITRAK DL, Estes R, Novak RM, Linnares-Diaz M, et al.
Beneficial Effects of a Switch to a Lopinavir/ritonavir (LPV/r)-Containing
Regimen for Patients with Partial or No Immune Reconstitution with Highly Active
Antiretroviral Therapy (HAART) Despite Complete Viral Suppression.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available


16. PEREZ R, Gibson S, Lopez P, Koenig E, et al.
Distribution of HIV-1 Infection in Different T Lymphocyte Subsets: Antiretroviral
Therapy-Naive vs. Experienced Patients.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available


17. LANDRUM ML, Hullsiek KH, Chun HM, Crum-Cianflone NF, et al.
The Timing of Hepatitis B Virus (HBV) Immunization Relative to Human
Immunodeficiency Virus (HIV) Diagnosis and the Risk of HBV Infection Following
HIV Diagnosis.
Am J Epidemiol. 2010.
ABSTRACT available


18. LEHMANN HC, Chen W, Borzan J, Mankowski JL, et al.
Mitochondrial dysfunction in distal axons contributes to human immunodeficiency
virus sensory neuropathy.
Ann Neurol. 2010.
ABSTRACT available


19. KOH Y, Haim H, Engelman A.
Identification and characterization of persistent intracellular human
immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
Antimicrob Agents Chemother. 2010.
ABSTRACT available


20. KLEVENS RM, Miller JT, Iqbal K, Thomas A, et al.
The evolving epidemiology of hepatitis a in the United States: incidence and
molecular epidemiology from population-based surveillance, 2005-2007.
Arch Intern Med. 2010;170:1811-8.
ABSTRACT available


21. PILCH-COOPER HA, Sieg SF, Hope TJ, Koons A, et al.
Circulating human CD4 and CD8 T cells do not have large intracellular pools of
CCR5.
Blood. 2010.
ABSTRACT available


22. COLLINS IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, et al.
Long-Term Survival of HIV-Infected Children Receiving Antiretroviral Therapy in
Thailand: A 5-Year Observational Cohort Study.
Clin Infect Dis. 2010.
ABSTRACT available


23. LE T, Huu Chi N, Kim Cuc NT, Manh Sieu TP, et al.
AIDS-Associated Penicillium marneffei Infection of the Central Nervous System.
Clin Infect Dis. 2010.
ABSTRACT available


24. SANCHEZ V, Masia M, Robledano C, Padilla S, et al.
A highly sensitive and specific model for predicting HIV-1 tropism in
treatment-experienced patients combining interpretation of V3 loop sequences and
clinical parameters.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available


25. WALENSKY RP, Wood R, Fofana MO, Martinson NA, et al.
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in
South Africa.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available


26. POLIS CB, Gray RH, Bwanika JB, Kigozi G, et al.
Effect of Hormonal Contraceptive Use Before HIV Seroconversion on Viral Load
Setpoint Among Women in Rakai, Uganda.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available


27. WOLFE D, Cohen J.
Human rights and HIV prevention, treatment, and care for people who inject drugs:
key principles and research needs.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S56-62.
ABSTRACT available


28. MONTANER JS, Wood E, Kerr T, Lima V, et al.
Expanded highly active antiretroviral therapy coverage among HIV-positive drug
users to improve individual and public health outcomes.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S5-9.
ABSTRACT available


29. BECKWITH CG, Zaller ND, Fu JJ, Montague BT, et al.
Opportunities to diagnose, treat, and prevent HIV in the criminal justice system.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S49-55.
ABSTRACT available


30. GULICK RM.
Antiretroviral treatment 2010: progress and controversies.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S43-8.
ABSTRACT available


31. FRIEDLAND G.
Infectious disease comorbidities adversely affecting substance users with HIV:
hepatitis C and tuberculosis.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S37-42.
ABSTRACT available


32. METZGER DS, Woody GE, O'Brien CP.
Drug treatment as HIV prevention: a research update.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S32-6.
ABSTRACT available


33. SCHACKMAN BR.
Implementation science for the prevention and treatment of HIV/AIDS.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S27-31.
ABSTRACT available


34. MARSHALL BD, Wood E.
Toward a comprehensive approach to HIV prevention for people who use drugs.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S23-6.
ABSTRACT available


35. STOCKMAN JK, Strathdee SA.
HIV among people who use drugs: a global perspective of populations at risk.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S17-22.
ABSTRACT available


36. BEYRER C, Wirtz AL, Baral S, Peryskina A, et al.
Epidemiologic links between drug use and HIV epidemics: an international
perspective.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S10-6.
ABSTRACT available


37. LAMBERT EY, Normand JL, Volkow ND.
Prevention and treatment of HIV/AIDS among drug-using populations: a global
perspective.
J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S1-4.



38. FUNG CHOW EP, Wilson DP, Zhang L.
The Next Era of HIV in China: Rapidly Spreading Epidemics Among Men Who Have Sex
With Men.
J Acquir Immune Defic Syndr. 2010;55:32-4.



39. JIA M, Sullivan SG, Lu L, Wu Z, et al.
Curbing the Rapid Spread of HIV Among MSM in China.
J Acquir Immune Defic Syndr. 2010;55:e33.



40. BALANDYA E, Sheth S, Sanders K, Wieland-Alter W, et al.
Semen Protects CD4+ Target Cells from HIV Infection but Promotes the Preferential
Transmission of R5 Tropic HIV.
J Immunol. 2010.
ABSTRACT available


41. XU H, Wang X, Pahar B, Moroney-Rasmussen T, et al.
Increased B7-H1 Expression on Dendritic Cells Correlates with Programmed Death 1
Expression on T Cells in Simian Immunodeficiency Virus-Infected Macaques and May
Contribute to T Cell Dysfunction and Disease Progression.
J Immunol. 2010.
ABSTRACT available


42. JONNALAGADDA S, Lohman Payne B, Brown E, Wamalwa D, et al.
Latent Tuberculosis Detection by Interferon gamma Release Assay during Pregnancy
Predicts Active Tuberculosis and Mortality in Human Immunodeficiency Virus Type
1-Infected Women and Their Children.
J Infect Dis. 2010.
ABSTRACT available


43. LING B, Mohan M, Lackner AA, Green LC, et al.
The Large Intestine as a Major Reservoir for Simian Immunodeficiency Virus in
Macaques with Long-Term, Nonprogressing Infection.
J Infect Dis. 2010.
ABSTRACT available


44. EDEN A, Fuchs D, Hagberg L, Nilsson S, et al.
HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive
Antiretroviral Treatment.
J Infect Dis. 2010.
ABSTRACT available


45. CLIFFORD DB.
Viral Escape in Cerebrospinal Fluid-An Achilles Heel of HIV Therapy?
J Infect Dis. 2010.



46. SCHMOKEL J, Sauter D, Schindler M, Leendertz FH, et al.
The presence of a vpu gene and lack of Nef-mediated down-modulation of TCR-CD3
are not always linked in primate lentiviruses.
J Virol. 2010.
ABSTRACT available


47. RABI SA, O'Connell KA, Nikolaeva D, Bailey JR, et al.
Unstimulated Primary CD4+ T Cells from HIV Type 1 Positive Elite Suppressors are
Fully Susceptible to HIV-1 Entry and Productive Infection.
J Virol. 2010.
ABSTRACT available


48. KOBAYASHI T, Ode H, Yoshida T, Sato K, et al.
Identification of amino acids in the human tetherin transmembrane domain
responsible for HIV-1 Vpu interaction and susceptibility.
J Virol. 2010.
ABSTRACT available


49. SHULLA A, Heald-Sargent T, Subramanya G, Zhao J, et al.
A transmembrane serine protease is linked to the SARS coronavirus receptor and
activates virus entry.
J Virol. 2010.
ABSTRACT available


50. WAUTERS O, Lebas E, Nikkels AF.
Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections.
J Am Acad Dermatol. 2010.
ABSTRACT available


51. Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
N Engl J Med. 2010;363:1968-70.
ABSTRACT available


52. TATTEVIN P, Arvieux C, Courpotin C.
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
N Engl J Med. 2010;363:1968-70.
ABSTRACT available


53. EKOUEVI DK.
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
N Engl J Med. 2010;363:1968-70.
ABSTRACT available


54. BELL DM, Brewinski MM, Holmes CB.
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission.
N Engl J Med. 2010;363:1968-70.
ABSTRACT available


55. JAHNICHEN S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, et al.
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis
and HIV-1 replication and mobilize stem cells.
Proc Natl Acad Sci U S A. 2010.
ABSTRACT available


56. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide
Presentation.
Science. 2010.
ABSTRACT available


57. CARTER GC, Bernstone L, Baskaran D, James W, et al.
HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin,
Rac1 and Pak1.
Virology. 2010.
ABSTRACT available


58. TUGIZOV SM, Herrera R, Veluppillai P, Greenspan D, et al.
HIV is inactivated after transepithelial migration via adult oral epithelial
cells but not fetal epithelial cells.
Virology. 2010.
ABSTRACT available


59. PEDERSEN R, Lohse N, Ostergaard L, Sogaard O, et al.
The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected
adults: a systematic review.
HIV Med. 2010 Nov 8. doi: 10.1111/j.1468-1293.2010.00892.
ABSTRACT available


60. CESCON A, Cooper C, Chan K, Palmer A, et al.
Factors associated with virological suppression among HIV-positive individuals on
highly active antiretroviral therapy in a multi-site Canadian cohort.
HIV Med. 2010 Nov 8. doi: 10.1111/j.1468-1293.2010.00890.
ABSTRACT available


61. SHIH TY, Chen KF, Rothman R, Hsieh YH, et al.
US national estimation of emergency department utilization by patients given
'HIV/AIDS-related illness' as their primary diagnosis.
HIV Med. 2010 Nov 8. doi: 10.1111/j.1468-1293.2010.00888.
ABSTRACT available


62. CAHN P, Altclas J, Martins M, Losso M, et al.
Antiviral activity of apricitabine in treatment-experienced HIV-1-infected
patients with M184V who are failing combination therapy.
HIV Med. 2010 Nov 3. doi: 10.1111/j.1468-1293.2010.00887.
ABSTRACT available


63. WATERS L, Fisher M, Anderson J, Wood C, et al.
Responses to highly active antiretroviral therapy and clinical events in patients
with a low CD4 cell count: late presenters vs. late starters.
HIV Med. 2010 Nov 3. doi: 10.1111/j.1468-1293.2010.00881.
ABSTRACT available


_____________________ ** End ** ______________________



We have screened the following journals for you:
AIDS
AIDS Clin Care
AIDS Read
AIDS Res Hum Retroviruses
Am J Epidemiol
Am J Hematol
Am J Med
Ann Intern Med
Ann Neurol
Antimicrob Agents Chemother
Antivir Ther
Arch Dermatol
Arch Dis Child
Arch Intern Med
Arch Neurol
Blood
BMJ
Br J Dermatol
Br J Haematol
Cancer
Cell
Clin Infect Dis
Dermatology
Drugs
HIV Med
Immunology
Int J Cancer
Int J Dermatol
J Acquir Immune Defic Syndr
J Am Acad Dermatol
J Clin Immunol
J Clin Invest
J Clin Oncol
J Immunol
J Infect Dis
J Med Virol
J Pediatr
J Virol
JAMA
Lancet
MMWR
N Engl J Med
Nat Med
Nature
Neurology
Pediatr Infect Dis J
Pediatrics
Proc Natl Acad Sci U S A
Scand J Infect Dis
Science
Vaccine
Virology

_________________________________________________________

No comments:

Post a Comment